サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：コンジュゲートワクチンの世界市場（2022年～2028年）
市場調査レポート
商品コード
1215609

コンジュゲートワクチンの世界市場（2022年～2028年）

Conjugate Vaccine Market 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
コンジュゲートワクチンの世界市場（2022年～2028年）
出版日: 2023年02月01日
発行: Orion Market Research
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のコンジュゲートワクチンの市場規模は、予測期間中に10.2%のCAGRで成長すると予測されています。当市場を牽引する主な要因には、肺炎球菌疾患の増加や、血液感染症、耳感染症、敗血症の症例が世界中で増加していることなどがあります。

当レポートでは、世界のコンジュゲートワクチン市場を調査し、市場の概要、市場の促進要因・抑制要因の分析、市場機会、セグメント別、地域別の市場分析、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向

第3章 競合情勢

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析
  • 主要企業に対するCOVID-19の影響

第4章 市場セグメンテーション

  • 世界のコンジュゲートワクチン市場：製品タイプ別
    • 多価コンジュゲートワクチン
    • 一価コンジュゲートワクチン
  • 世界のコンジュゲートワクチン市場：疾患別
    • 髄膜炎菌
    • ジフテリア破傷風百日咳
    • インフルエンザ
    • 肺炎球菌
    • その他
  • 世界のコンジュゲートワクチン市場：患者タイプ別
    • 成人
    • 小児
  • 世界のコンジュゲートワクチン市場：病原体タイプ別
    • 細菌コンジュゲートワクチン
    • ウイルスコンジュゲートワクチン
    • 混合ワクチン

第5章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他の欧州
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他のアジア太平洋地域
  • 世界のその他の地域

第6章 企業プロファイル

  • Astellas Pharma Inc.
  • Astrazeneca
  • Bharat Biotech
  • Biological E Ltd.
  • Bavarian Nordic
  • CSL Behring
  • Daiichi Sankyo Company, Ltd.
  • Emergent BioSolutions, Inc
  • Glaxosmithkline Plc.
  • Johnson & Johnson
  • Merck & Co.
  • Mitsubishi Tanabe Pharma Corp
  • Medimmune, LLC
  • Neuron Biotech
  • Novartis AG
  • Sanofi Pasteur
  • SutroVax Inc.
  • Pfizer, Inc.
  • Serum Institute Of India Pvt. Ltd
図表

LIST OF TABLES

  • 1. GLOBAL CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2021-2028($ MILLION)
  • 2. GLOBAL MULTIVALENT CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL MONOVALENT CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2021-2028 ($ MILLION)
  • 5. GLOBAL CONJUGATE VACCINE FOR MENINGOCOCCAL, MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL CONJUGATE VACCINE FOR DIPHTHERIA TETANUS PERTUSSIS, MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL CONJUGATE VACCINE FOR INFLUENZA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL CONJUGATE VACCINE FOR PNEUMOCOCCAL MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL CONJUGATE VACCINE FOR OTHER DISEASE, MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATIENT TYPE, 2021-2028 ($ MILLION)
  • 11. GLOBAL CONJUGATE VACCINE FOR ADULTS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 12. GLOBAL CONJUGATE VACCINE FOR PEDIATRICSMARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 13. GLOBAL CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATHOGEN TYPE, 2021-2028 ($ MILLION)
  • 14. GLOBAL BACTERIAL CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 15. GLOBAL VIRAL CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 16. GLOBAL COMBINATION CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 17. GLOBAL CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 18. NORTH AMERICAN CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 19. NORTH AMERICAN CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2021-2028 ($ MILLION)
  • 20. NORTH AMERICAN CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2021-2028 ($ MILLION)
  • 21. NORTH AMERICAN CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATIENT TYPE, 2021-2028 ($ MILLION)
  • 22. NORTH AMERICAN CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATHOGEN TYPE, 2021-2028 ($ MILLION)
  • 23. EUROPEAN CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 24. EUROPEAN CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2021-2028 ($ MILLION)
  • 25. EUROPEAN CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2021-2028 ($ MILLION)
  • 26. EUROPEAN CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATIENT TYPE, 2021-2028 ($ MILLION)
  • 27. EUROPEAN CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATHOGEN TYPE, 2021-2028 ($ MILLION)
  • 28. ASIA-PACIFIC CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 29. ASIA-PACIFIC CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2021-2028 ($ MILLION)
  • 30. ASIA-PACIFIC CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2021-2028 ($ MILLION)
  • 31. ASIA-PACIFIC CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATIENT TYPE, 2021-2028 ($ MILLION)
  • 32. ASIA-PACIFIC CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATHOGEN TYPE , 2021-2028 ($ MILLION)
  • 33. REST OF THE WORLD CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 34. REST OF THE WORLD CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2021-2028 ($ MILLION)
  • 35. REST OF THE WORLD CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2021-2028 ($ MILLION)
  • 36. REST OF THE WORLD CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATIENT TYPE, 2021-2028 ($ MILLION)
  • 37. REST OF THE WORLD CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATHOGEN TYPE, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL CONJUGATE VACCINE MARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL CONJUGATE VACCINE MARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBAL CONJUGATE VACCINE MARKET, 2021-2028 (%)
  • 4. GLOBAL CONJUGATE VACCINE MARKET SHARE BY PRODUCT TYPE, 2021 VS 2028 (%)
  • 5. GLOBAL MULTIVALENT CONJUGATE VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL MONOVALENT CONJUGATE VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL CONJUGATE VACCINE MARKET SHARE BY DISEASE, 2021 VS 2028 (%)
  • 8. GLOBAL CONJUGATE VACCINE FOR MENINGOCOCCAL MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 9. GLOBAL CONJUGATE VACCINE MARKET FOR DIPHTHERIA TETANUS PERTUSSIS SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 10. GLOBAL CONJUGATE VACCINE FOR INFLUENZA MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 11. GLOBAL CONJUGATE VACCINE FOR PNEUMOCOCCAL MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. GLOBAL CONJUGATE VACCINE FOR OTHER DISEASE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL CONJUGATE VACCINE MARKET SHARE BY PATIENT TYPE, 2021 VS 2028 (%)
  • 14. GLOBAL CONJUGATE VACCINE FOR ADULTS MARKET SHARE BY GEOGRAPHY 2021 VS 2028 (%)
  • 15. GLOBAL CONJUGATE VACCINE FOR PEDIATRICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 16. GLOBAL CONJUGATE VACCINE MARKET SHARE BY PATHOGEN TYPE, 2021 VS 2028 (%)
  • 17. GLOBAL BACTERIAL CONJUGATE VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 18. GLOBAL VIRAL CONJUGATE VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 19. GLOBAL COMBINATION CONJUGATE VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 20. US CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. CANADA CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. UK CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. FRANCE CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. GERMANY CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. ITALY CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. SPAIN CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. REST OF EUROPE CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 28. INDIA CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 29. CHINA CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 30. JAPAN CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 31. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 32. REST OF ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 33. REST OF THE WORLD CONJUGATE VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
目次
Product Code: OMR2026665

Title:Global Conjugate Vaccine Market Size, Share & Trends Analysis Report By Product Type (Multivalent Conjugate Vaccines, Monovalent Conjugate Vaccines) By Disease (Meningococcal, Diphtheria Tetanus Pertussis, Influenza, Pneumococcal, and Others) By Patient Type (Adults and Pediatric) By Pathogen Type (Bacterial Conjugate Vaccine, Viral Conjugate Vaccine and Combination Vaccine) Forecast 2022-2028.

The global conjugate vaccine market is anticipated to grow at a substantial CAGR of 10.2% during the forecast period. The increasing number of pneumococcal disease is significantly growing the market for conjugate vaccine. Conjugate vaccine can be used for several different infections. The growing cases of blood infection , ear infection , sepsis across the globe, are in turn contributing to the growth of the global conjugate vaccine market. For instance, according to WHO, report published on 8 September 2020, sepsis kills 11 million people each year, many of them children. Around half of the 49 million cases of sepsis each year occur among children, resulting in 2.9 million deaths.

The global conjugate vaccine market is segmented based on product type, disease, patient type and pathogen type. Based on product type the market is segmented into multivalent conjugate vaccines, and monovalent conjugate vaccines. Based on disease the market is bifurcated into meningococcal, diphtheria tetanus pertussis, influenza, pneumococcal, and others. Based on patient type the market is segmented into adults and pediatric. Based on pathogen type the market is segmented into bacterial conjugate vaccine, viral conjugate vaccine and combination vaccine. Based on disease the diphtheria tetanus pertussis segment is anticipated to grow at the fastest rate, due to the rising number of respiratory problems among geriatric population, paralysis, heart failure which is fueling the global conjugate vaccine market. According to WHO, 1 in 200 infections leads to irreversible paralysis and among those paralyzed, 5% to 10% die when their breathing muscles become immobilized.

Geographically market is segmented into: North America, Europe, Asia-Pacific, and the Rest of the World. North America dominates the market and is expected to continue its dominance over the forecast period. The growth can be attributed to the increasing number of infectious diseases and increasing adoption of conjugate vaccine. Due to awareness about meningococcal, diphtheria tetanus pertussis, influenza, pneumococcal, and other vaccine the demand for conjugate vaccine is set to increase over the coming years, which in turn, will contribute to the growth of the market in the North America region. According to Centre for Disease Control and Prevention (CDC), in the US, around 48.1% adults aged over 18 received influenza vaccination in 2019-2020.. Further the presence of key market players is also growing the demand for the conjugate vaccine. Also, around 14.4 people have been killed due to pneumonia in US.

The major companies serving the global conjugate vaccine market are Merck & Co., GlaxoSmithKline Plc., Bharat Biotech and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, partnership, collaborations, fundings, and new product launches, to stay competitive in the market. For instance, in 2021 Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial as per independent Monitoring Board recommendation.

Research Methodology

The market study of the global conjugate vaccine market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Conjugate vaccine Market Research and Analysis by Product Type
  • Global Conjugate vaccine Market Research and Analysis by Disease
  • Global Conjugate vaccine Market Research and Analysis by Patient Type
  • Global Conjugate vaccine Market Research and Analysis by Pathogen Type

The Report Covers:

  • Comprehensive research methodology of the global conjugate vaccine market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global conjugate vaccine market.
  • Insights about market determinants that are stimulating the global conjugate vaccine market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Conjugate vaccine Market
  • Recovery Scenario of Global Conjugate vaccine Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Ananlysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of Covid-19 on Key Players

4. Market Segmentation

  • 4.1. Global Conjugate Vaccine Market, by Product Type
    • 4.1.1. Multivalent Conjugate Vaccine
    • 4.1.2. Monovalent Conjugate Vaccine
  • 4.2. Global Conjugate Vaccine Market, by Disease
    • 4.2.1. Meningococcal
    • 4.2.2. Diphtheria Tetanus Pertussis
    • 4.2.3. Influenza
    • 4.2.4. Pneumococcal
    • 4.2.5. Others
  • 4.3. Global Conjugate Vaccine Market, by Patient type
    • 4.3.1. Adults
    • 4.3.2. Pediatric
  • 4.4. Global Conjugate Vaccine Market, by Pathogen type
    • 4.4.1. Bacterial Conjugate Vaccine
    • 4.4.2. Viral Conjugate Vaccine
    • 4.4.3. Combination Vaccine

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Astellas Pharma Inc.
  • 6.2. Astrazeneca
  • 6.3. Bharat Biotech
  • 6.4. Biological E Ltd.
  • 6.5. Bavarian Nordic
  • 6.6. CSL Behring
  • 6.7. Daiichi Sankyo Company, Ltd.
  • 6.8. Emergent BioSolutions, Inc
  • 6.9. Glaxosmithkline Plc.
  • 6.10. Johnson & Johnson
  • 6.11. Merck & Co.
  • 6.12. Mitsubishi Tanabe Pharma Corp
  • 6.13. Medimmune, LLC
  • 6.14. Neuron Biotech
  • 6.15. Novartis AG
  • 6.16. Sanofi Pasteur
  • 6.17. SutroVax Inc.
  • 6.18. Pfizer, Inc.
  • 6.19. Serum Institute Of India Pvt. Ltd